Highlights from our recent joint whitepaper with Bristol Myers Squibb

• Successful quantification of heterogeneous sub-populations of AAV across a range of different matrices and manufacturing processes.
• Proposal of the ratio of full-length versus total packaged viral genome species to assess AAV product quality and manufacturing performance. This ratio emphasizes the impact of packaged truncated species and distinguishes from the typical percent full measurement.
• The nanoneedle technology is an attractive approach to quantify the true full-length transgene of interest versus truncated partial transgenes that can persist in AAV feed streams throughout the manufacturing process.